Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


We employ our advanced, specialised process to create targeted libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
Q06265

UPID:
EXOS9_HUMAN

ALTERNATIVE NAMES:
Autoantigen PM/Scl 1; Exosome component 9; P75 polymyositis-scleroderma overlap syndrome-associated autoantigen; Polymyositis/scleroderma autoantigen 1; Polymyositis/scleroderma autoantigen 75 kDa

ALTERNATIVE UPACC:
Q06265; Q12883; Q4W5P5; Q86Y41; Q86Y48

BACKGROUND:
The Exosome complex component RRP45, known for its alternative names such as Autoantigen PM/Scl 1 and Polymyositis/scleroderma autoantigen 75 kDa, is integral to the RNA exosome complex. This complex is pivotal in RNA processing, affecting the maturation of rRNA, snRNA, and snoRNA, and the degradation of defective mRNAs and non-coding transcripts.

THERAPEUTIC SIGNIFICANCE:
Given its critical role in Pontocerebellar hypoplasia 1D, a disorder characterized by motor neuronopathy and cerebellar atrophy, Exosome complex component RRP45 presents a promising target for therapeutic intervention. Exploring its functions further could lead to breakthroughs in treating this debilitating disease.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.